Several studies have been focused on identifying alternative medicines for the treatment of cancer. This study aimed to investigate the impact of B-Glucans extract (BG) against Ehrlich Ascites Carcinoma (EAC) induced toxicity and tissue damage in kidney. A total of 40 mice were assigned randomly to four groups (G1, control; G2, B-Glucans (75 mg/kg bw/day) orally for 2 weeks; G3, EAC and G4, EAC + BG). Current results revealed, EAC induced significant elevation in urea, creatinine, potassium (k+), chloride (Cl-) ions, kidney injury and significant decrease in sodium (Na+) and calcium (Ca++) ions when compared to B-glucans and control groups. Conversely, EAC + B-glucans modulate these changes and improved the renal functions and structure. EAC induced renal dysfunction and B-Glucans has the ability to improve renal functions. We can conclude that; BG could be used as an adjuvant therapy for kidney in ascites of hepatocellular carcinoma, Schistosoma and hepatitis.

Obesity has been linked to several chronic diseases, including fatty liver disease, fatty heart disease, diabetes mellitus, hypertension, obstructive sleep apnea, and cancer. The purpose of the current study was to determine how Orlistat affected renal toxicity, DNA damage, and apoptosis that were brought on by obesity in normal and obese female rats. There were four groups made up of a total of 20 female rats (G1, Control; G2, Orlistat; G3, Obesity; G4, treated obesity with Orlistat rat group). The results of the present investigation showed that orlistat treatment resulted in kidney injury, DNA damage, and P53 mutations as well as a large increase in serum urea and creatinine levels as well as a significant drop in sodium, potassium, calcium, and chloride ions levels. Therefore, when administered to treat normal or obese rats, orlistat caused kidney damage; as a result, doctors should carefully monitor it.